Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72$119.6 million, representing growth of 84% year-over-year and 24% sequentially SUNOSI ® 2Q 2025 net product revenue of $30.0 million, representing growth of 35% year-over-year and 19% sequentially SYMBRAVO® launched June 10 th , with 2Q 2025 net pr ...